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Abstract Recent data has indicated that Zn can modulate
serotonergic function through the 5-HT1A receptor (5-
HT1AR); however, the exact mechanisms are unknown. In
the present studies, radioligand binding assays and behaviour-
al approaches were used to characterize the pharmacological
profile of Zn at 5-HT1ARs in more detail. The influence of Zn
on agonist binding to 5-HT1ARs stably expressed in HEK293
cells was investigated by in vitro radioligand binding methods
using the agonist [3H]-8-OH-DPAT. The in vivo effects of Zn
were compared with those of 8-OH-DPAT in hypothermia,
lower lip retraction (LLR), 5-HT behavioural syndrome and
the forced swim (FST) tests. In the in vitro studies, biphasic
effects, which involved allosteric potentiation of agonist bind-
ing at sub-micromolar Zn concentrations and inhibition at
sub-millimolar Zn concentrations, were found. The in vivo
studies showed that Zn did not induce LLR or elements of
5-HT behavioural syndrome but blocked such effects induced
by 8-OH-DPAT. Zn decreased body temperature in rats and
mice; however, Zn failed to induce hypothermia in the 5-HT1A
autoreceptor knockout mice. In the FST, Zn potentiated the
effect of 8-OH-DPAT. However, in the FST performed with
the 5-HT1A autoreceptor knockout mice, the anti-immobility
effect of Zn was partially blocked. Both the binding and be-
havioural studies suggest a concentration-dependent dual
mechanism of Zn action at 5-HT1ARs, with potentiation at
low dose and inhibition at high dose. Moreover, the in vivo
studies indicate that Zn can modulate both presynaptic and
postsynaptic 5-HT1ARs; however, Zn’s effects at presynaptic
receptors seem to be more potent.
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Zinc (Zn) is an essential trace element that is required for
proper brain function [1]. Zn modulates neuronal excitability,
plays an important role in synaptic plasticity and can function
as a signalling molecule [2, 3]. Recent data have indicated that
disturbances in Zn homeostasis are involved in the aetiology
of some neurological disorders. Several studies, including
both preclinical and clinical studies, showed that Zn deficien-
cy leads to the development of depression [4–6] and that Zn
supplementation improves the effectiveness of standard anti-
depressant treatment [7, 8]. One of the possible mechanisms
involved in Zn antidepressant activity is the modulation of the
serotonergic system through 5-HT1A and 5-HT2A receptors [9,
10]. Zn was found to enhance the effect of citalopram and
fluoxetine in the forced swim test (FST) in mice, and pretreat-
ment with an inhibitor of serotonin synthesis, p-
chlorophenylalanine (pCPA), blocked the antidepressant-like
effect observed in the FST [10]. Moreover, the fact that rats
show an increase in the swimming but not the climbing pa-
rameter in the FST following Zn administration indicates (ac-
cording to the observation of Detke et al. [11]) the involve-
ment of the serotonin pathway in the effects of Zn in the FST
[10]. Additionally, it was found that the antidepressant-like
effect of Zn in the FST in mice was blocked by the 5-HT1AR
antagonist WAY-100635, which suggested that the modula-
tion of the serotonergic system by Zn is mediated mostly
through the 5-HT1AR [10].
Further evidence for the postulated direct link between Zn
and 5-HT1AR were recently provided by Tena-Campos et al.
[12] who showed the impact of Zn homeostasis on the balance
between monomers/heterodimers of 5-HT1A and galanin 1
receptor (GalR1). The latter protein was indicated as being
involved in major depressive disorder by modulating 5-
HT1A functionality via specific heterodimerization process
[12].
The direct modulatory effect of Zn at the 5-HT1ARwas also
reported by Barrondo and Salles, who described negative al-
losteric modulatory properties of Zn ions against antagonist
([3H]-WAY-100635) and agonist ([3H]-8-OH-DPAT) binding
at 5-HT1ARs in cortical membranes isolated from the rat brain
[13]. It should be noted, however, that the changes observed
for [3H]-8-OH-DPAT (i.e. a decrease of dissociation constant
(KD) and Bmax values were demonstrated through saturation
experiments only and were complex and difficult to interpret.
Moreover, although studies using native tissue have strong
biological significance, membranes prepared from rat cerebral
cortex contain other receptors that can be targeted by [3H]-8-
OH-DPAT (i.e. serotonin 5-HT7 receptors and α-2 adrenergic
receptors) [14, 15], which might create an additional level of
complexity in the interactions of Zn at 5-HT1ARs. As alloste-
ric modulation is strongly probe-dependent [16], evaluation of
the effects of Zn on agonist binding is of primary importance
to its action observed in vivo. Thus, we performed in vitro
radioligand experiments to gain further mechanistic insight
into the nature of Zn interactions at 5-HT1ARs. In the present
study, HEK293 cells expressing 5-HT1A (5-HT1A) receptors
were used, which provides a homogeneous system to study
effects solely attributable to the 5-HT1AR subtype. The influ-
ence of Zn ions on agonist binding was investigated by satu-
ration, competition and both association and dissociation ki-
netic studies using [3H]-8-OH-DPAT, a 5-HT1AR agonist.
Due their localization, neuronal 5-HT1ARs are divided into
two different classes: the 5-HT1A autoreceptors located on the
soma and dendrites of serotonergic neurons in the raphe nu-
cleus and the heteroreceptors expressed postsynaptically in
the prefrontal cortex (PFC), amygdala and hippocampus [17,
18]. The activation of 5-HT1AR has been shown to induce a
number of behavioural responses, including lower lip retrac-
tion (LLR), flat body posture (FBP), forepaw treading (FT),
and a decrease in body temperature [19–23]. The ability of
compounds to induce or block these behaviours is commonly
used to differentiate and characterize their activity at pre- or
postsynaptic 5-HT1ARs. Therefore, in addition to the binding
assays, we assessed the ability of Zn to produce LLR, FBP and
FT in rats. We also studied both the capacity of Zn to induce
hypothermia and the activity of Zn in the FST in rats as well as




[3H]-8-OH-DPAT (135.2 Ci/mmol) was purchased from
PerkinElmer and (R)-(+)-8-OH-DPAT, 5-HT and ZnCl2 were
obtained from Sigma-Aldrich.
Expression of the Gene for the Human 5-HT1AR
The full-length human 5HTR1A complementary DNA
(cDNA), which was cloned into the mammalian expression
vector pcDNA3.1(+), was obtained from the Missouri S&T
cDNA Resource Center (www.cdna.org). The receptor cDNA
was stably transfected into human embryonic kidney cells
(HEK293, ATCC) with the use of Lipofectamine 2000
(Invitrogen). A clone yielding a high expression level of 5-
HT1AR was selected during preliminary experiments,
including RT-PCR and Western blot analysis.
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Cell Culture and Preparation of Cell Membranes
HEK293 cells with stable expression of 5-HT1AR were main-
tained at 37 °C in a humidified atmosphere with 5 % CO2 and
were grown in Dulbecco’s Modified Eagle Medium (Lonza
Ltd.) containing 10 % dialysed foetal bovine serum (Lonza
Ltd.) and 500 μg/ml G418 sulphate (Sigma-Aldrich). For
membranes preparations, the cells were subcultured in
150 cm2 flasks, grown to 90% confluence, washed twice with
phosphate buffered saline (PBS) prewarmed to 37 °C and
pelleted by centrifugation (200g for 5 min) in PBS containing
0.1 mM EDTA and 1 mM dithiothreitol. Prior to membrane
preparation, the pellets were stored at −80 °C.
Preparation of Membranes for Radioligand Binding Assays
Cell pellets were thawed and homogenized in 20 volumes of
50 mM Tris–HCl buffer (pH 7.7) containing 0.1 mM EDTA
and 10 mMMgCl2, using an Ultra Turrax tissue homogenizer.
The pellets were then centrifuged twice at 35,000g for 20 min
at 4 °C, with incubation for 15 min at 37 °C in between
centrifugations. Membranes were aliquoted in tubes. Mem-
brane protein concentrations were determined using the
Pierce™ Coomassie (Bradford) Protein Assay Kit, with bo-
vine serum albumin (BSA) as a standard.
Radioligand Binding Assays
[3H]-8-OH-DPATwas used as a selective 5-HT1AR agonist.
The affinity (KD) and maximal number of binding sites
(Bmax) were measured by saturation binding experiments
over a radioligand concentration range of 0.1–14 nM. The
affinity shift was determined by measuring the KD obtained
in saturation binding assays performed in the absence and
presence of six concentrations of Zn (0.01–5 mM). Com-
petition studies were performed with 2.5 nM of [3H]-8-OH-
DPAT in the presence of various concentrations of
orthosteric agonist serotonin in the absence and presence
of Zn at two concentrations (10 and 500 μM). Non-
specific binding was estimated in the presence of 10 μM
5-HT. The incubation buffer consisted of 50 mM Tris–HCl
(pH 7.7), 10 mM MgCl2, 10 mM pargyline and 0.1 %
ascorbic acid. Radioligand binding assays were performed
by incubating 30 μg of protein of the membrane suspen-
sion in 96-well microtitre plates for 60 min at room tem-
perature with shaking, in a total volume of 200 μl. The
binding reactions were stopped by filtration through GF/C
Unifilter plates using a harvester (PerkinElmer). The plate
filters were dried, and 20 μl of Ultima Gold MV
(PerkinElmer) was added. Radioactivity was measured
using a MicroBeta TriLux counter (PerkinElmer).
Association and Dissociation Assays
Association and dissociation rate kinetic assays were per-
formed at room temperature using the same buffer conditions
described for the equilibrium binding assays and 2.5 nM [3H]-
8-OH-DPAT. Non-specific binding was defined by the addi-
tion of 10 μM serotonin. The amount of radioligand bound to
the receptor was measured at different time intervals during a
total incubation of 60min in the absence or presence of 10 and
500 μMZnCl2. For the dissociation assay, after incubating the
membranes with radioligand for 60 min to achieve equilibri-
um, serotonin (10 μM), either alone or together with 10 or
500 μM of ZnCl2, was added, and the specifically bound
radioligand was measured after incubations of different dura-
tions (from 0 to 60 min), which were terminated by rapid
filtration.
Data Analysis
All experiments were performed in triplicate, and the results
were obtained from at least three independent experiments.
The data are expressed as the mean±S.D. (standard devia-
tion). The experimental data were analysed using GraphPad
Prism 5.1 for Windows (GraphPad Software, San Diego Cal-
ifornia USA, www.graphpad.com). Analysis of the saturation
binding data with respect to allosteric interactions was
performed with the use of equation (1) [24]:
pKApp ¼ −log B½  þ 10logKB
 þ log α B½  þ 10logKB −logd
where KApp is the apparent equilibrium dissociation con-
stant of radioligand A ([3H]-8-OH-DPAT) observed in the
presence of modulator B (ZnCl2); KA and KB are the equilib-
rium dissociation constants of the radioligand and allosteric
modulator, respectively; logd is a constant representing the
logarithm of the quotient of KA and α; and α defines the
cooperativity factor, the magnitude by which the equilibrium
dissociation constant of either ligand for its site on the receptor
is modified by the concomitant presence of the other ligand.
Values of α less than 1 (but greater than zero) denote negative
cooperativity, values greater than 1 denote positive
cooperativity and values not significantly different from 1
indicate neutral cooperativity.
Bell-shaped concentration-response curves were fit to a
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where ρA denotes the fractional receptor occupancy by the
orthosteric ligand; [A] and [B] are the concentrations of
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[3H]-8-OH-DPAT and ZnCl2, respectively; KA, KB1, and KB2
denote equilibrium dissociation constants; the subscript ‘1’
refers to the binding of B to the orthosteric site; the subscript
‘2’ refers to the binding of B to the allosteric site; the
cooperativity factor α′ denotes the interaction between B and
A; and β denotes the interaction between the two molecules of
B.
The experimental data were fit to one-site and two-site
models to determine the best fit. The statistical significance
of differences between the means was evaluated by Student’s t
test. The level of significance was set at p<0.05.
Behavioural Studies
Animals and Housing
The experiments were performed on male Albino Swiss mice
(23–25 g) and Sprague Dawley rats (200–250 g) from Charles
River, Germany as well as TPH2-Cre-ERT2 x flx-5-HT1A-flx-
YFP mice from Jackson Labs, Bangor ME and the Hen lab,
respectively. The animals were kept under standard laboratory
conditions with respect to lighting (light phase 7:00–19:00)
and temperature (19–21 °C). Food and water were freely
available. Each experimental group consisted of eight to ten
animals. All of the animals were experimentally naive and
were used only once in each test. The experiments were per-
formed during the light period (9:00–14:00 h). All of the pro-
cedures were conducted according to the guidelines of the
National Institutes of Health Animal Care and Use Committee
and were approved by the Ethics Committees of the Institute
of Pharmacology, Polish Academy of Sciences in Krakow and
the Animal Care Committee, University of Ottawa.
Drug Administration
Zn (all doses refer to mg Zn/kg) was given as either Zn
hydroaspartate (Farmapol, Poland) or Zn chloride (Sigma-
Aldrich) and was dissolved in 0.9 % NaCl and administered
intraperitoneally (i.p.). 8-OH-DPAT and WAY-100635 were
dissolved in aqua pro-injection and were administered subcu-
taneously (s.c.). Controls were treated with the appropriate
diluent, which was indicated as VEH on the graphs and in
the tables.
Presynaptic 5-HT1AR Knockout Mice
A conditional knockout approach was used to eliminate the 5-
HT1AR in the raphe nuclei in adult mice. To create the condi-
tional 5-HT1AR knockout mice, a TPH2-Cre-ER
T2 mouse line
was crossed with a flx-5-HT1A-YFP mouse line. The TPH2-
Cre-ERT2 confers specificity such that only serotonin neurons,
which express tryptophan hydroxylase 2 (TPH2), can express
Cre recombinase to knockout the 5-HT1AR gene and allow for
GFP expression [25]. Once the mice reached adulthood (ap-
proximately 5–6 postnatal weeks), tamoxifen (180 mg/kg)
was injected i.p. every day for five consecutive days (the ta-
moxifen binds to the ERT2 domain and enables Cre to enter
the nucleus where it can excise the 5-HT1AR gene, allowing
for YFP expression as a marker of recombination). The mice
were then left undisturbed for at least 14 days to allow for
recombination and the turnover of endogenous 5-HT1ARs.
Lower Lip Retraction
LLR was assessed according to the method described by
Berendsen et al., [20]. The rats were individually placed in
cages (30×25×25 cm) and were scored three times, 15, 30
and 45 min after the administration of Zn as follows: 0=lower
incisors not visible, 0.5=partly visible and 1=completely vis-
ible. Zn was administered at doses of 2 and 5 mg Zn/kg (given
as Zn hydroaspartate, Farmapol, Poland). The maximum total
score was 3/rat. In addition, the effects of Zn and WAY-
100635 (0.1 mg/kg; Sigma) on the LLR induced by 8-OH-
DPAT (1 mg/kg; Sigma) were tested. Zn and WAY-100635
were administered 45 min before 8-OH-DPAT, and the ani-
mals were scored 15, 30 and 45 min after the 8-OH-DPAT
administration.
Behavioural Syndrome
The experiments were conducted according to previously
published procedure [26], with a modification to the ranked
intensity scale. Briefly, the rats were individually placed in
cages (30×25×25 cm) 5 min before tested compounds were
injected. Forepaw treading (FT) and flat body posture (FBP)
were scored using a ranked intensity scale, where 0=absent,
1=equivocal and 2=present. The Zn (2, 5, 7.5 and 11.5 mg
Zn/kg, given as a Zn hydroaspartate)-induced behavioural
syndrome was scored for each animal 3, 6, 9, 12 and 15 min
after the Zn treatment. Each observation session lasted for
45 s. The maximum score, which was summed over 5 obser-
vation periods, was 10 for each symptom/rat. The effect of Zn
on the behavioural syndrome induced by 8-OH-DPAT
(5 mg/kg) was scored using the same scale. Zn was
administered 60 min before 8-OH-DPAT, and the animals were
scored 3, 6, 9, 12 and 15 min after the 8-OH-DPAT treatment.
Body Temperature in Mice and Rats
The effects of Zn (2, 5, 7.5 and 11.5 mg Zn/kg for rats and 2
and 5 mg/kg for mice, given as a Zn hydroaspartate), 8-OH-
DPAT (5 mg/kg) andWAY-100635 (0.1mg/kg) on rectal body
temperature were recorded 30 and 60 min after their acute
administration. The results were expressed as a change in
body temperature with respect to the basal body temperature,
which was measured at the beginning of the experiments.
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Body Temperature in 5-HT1A Autoreceptor KO Mice
A separate experiment was performed to measure the effect of
Zn on rectal body temperature in wild-type and 5-HT1A
autoreceptor KO mice; however, in this experiment, only the
higher dose of Zn (5 mg Zn/kg; Zn chloride, Sigma) was used.
Forced Swim Test (FST)
Rats The test was carried out according to the method de-
scribed previously [10]. On day one of the experiment, the
animals were individually placed in plexiglass cylinders
(40 cm in height, 18 cm in diameter), containing 25 cm of
water maintained at 24–25 °C for a 15-min habituation period.
After the rats were removed from the water, they were again
placed in their home cages. On the second day, the rats were
again placed in the cylinders, and the total duration of immo-
bility was measured for a 5-min test period. Zn (1 or 2 mg Zn/
kg, given as Zn hydroaspartate) and 8-OH-DPAT (0.1 or
0.3 mg/kg) were administered alone or jointly 30 min before
the test. WAY-100635 (0.1 mg/kg) was administered 15 min
before the Zn treatment.
5-HT1A Autoreceptor KO Mice The behaviour of the mice
in the water was recorded using a video camera. The test was
performed under red lighting. The cylinder was filled with
almost 4 l of water, to a depth that exceeded the distance to
which the tail could extend, so the mouse could not balance on
its tail at the bottom of the cylinder. The top of the cylinder
was 9 cm above the surface of the water. Themicewere placed
in the individual glass cylinder (22 cm diameter×37 cm high)
for a standard 6-min test; however, the total duration of im-
mobility from the last 4 min of the test was analysed. In this
test, only one dose of Zn—5 mg Zn/kg (given as a Zn chlo-
ride)—was administered 30 min before the test.
Data Analysis
One-way ANOVA followed by Dunnett’s multiple compari-
son test (LLR, FBP, FT and FST) or Student’s t test (FST and
body temperature in wild-type and 5-HT1A autoreceptor KO
mice) was used, and p<0.05 was considered significant.
Results
Receptor Binding Studies
The binding of [3H]-8-OH-DPAT to 5-HT1ARs was saturable,
yielding an equilibrium constant of KD=2.9±0.1 nM (n=4)
and a maximal receptor binding of Bmax=4.5±0.3 pM/mg
prot. Saturation isotherms obtained for six increasing concen-
trations of Zn (10 μM–5 mM) revealed a decrease in
radioligand binding (Fig. 1a). The KD values for [
3H]-8-OH-
DPAT increased from 5 nM at 10μMof Zn to 9.6 nM at 5 mM
of Zn relative to theKD obtained for [
3H]-8-OH-DPATwithout
Zn (Table 1). At the same time, unusual changes in Bmax
values were observed. Zn at 10 μM caused an increase in
specific binding (Bmax=5.8±0.7 pM/mg prot.), Zn at 0.5 and
1 mM recovered the control values (4.7±0.7 and 4.0±0.6 pM/
mg prot., respectively), and the two highest concentrations of
Zn (2.5 and 5 mM) significantly decreased Bmax values (3.1±
1.0 and 2.2±0.8 pM/mg prot., respectively).
The data derived from the saturation experiments were fit
using nonlinear regression according to equation 1 (Fig. 1b),
and the calculated value of the cooperativity factor (α=0.37)
indicated negative modulation between the binding of Zn and
the agonist radioligand. This is generally consistent with the
results described by Barrondo and Salles for rat cortical mem-
branes, except that increased Bmax values at lower Zn concen-
trations were not observed in their saturation studies [13].
Next, a Zn titration curve against a single, fixed concentra-
tion of [3H]-OH-DPAT (2.5 nM) was evaluated in
competition-like experiments. As observed in Fig. 2a, a bell-
shaped binding curve was obtained, with an ~25% increase of
[3H]-8-OH-DPAT specific binding at 10 μM of Zn and subse-
quent inhibition at >100 μM. This type of binding is charac-
teristic of ligands exhibiting some degree of allosteric en-
hancement; therefore, the classic model of negative
cooperativity is not a complete description of the action of
Zn ions on agonist binding at 5-HT1ARs. Thus, it was inter-
esting to check the influence of Zn ions on serotonin (as an
endogenous orthosteric agonist) in displacement experiments
in the absence and presence of 10 and 500 μM of Zn. The 5-
HT tested alone completely inhibited [3H]-8-OH-DPAT bind-
ing at 5-HT1ARs, with a Ki of 8.7±0.6 nM; addition of 10 μM
of Zn ions caused a small but significant reduction of Ki value
for 5-HT (Ki=5.4±0.2 nM, p<0.05, F test), while at higher Zn
concentrations the affinity of 5-HT remained unchanged (Ki=
8.1±0.6 nM). Figure 2b shows a representative set of inhibi-
tion curves of [3H]8-OH-DPAT for 5-HT obtained in the ab-
sence and presence of Zn ions.
Kinetic Studies
It is well known that allosteric modulators may increase or
decrease the association and/or dissociation rates of an
orthosteric ligand at its binding site in a way that enhancers
increase the association rate and/or decrease the dissociation
rate, whereas negative allosteric modulators act in the opposite
way. On the other hand, competitive orthosteric ligands can
influence the association rate by increasing the time needed
for the radioligand to reach equilibrium, but do not change the
dissociation rate [27].
Taking into account the complex mechanism of Zn influ-
ence on agonist binding, dissociation and association (see
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Fig. 3) rates were measured in kinetic assays; the values of
kinetic parameters are listed in Table 2.
In the absence of Zn, the dissociation rate for [3H]-8-
OH-DPAT at 5-HT1ARs was biphasic, and it remained
biphasic at high Zn concentration, but both phases were
significantly reduced without affecting the proportion of
each state. However, the presence of a low concentra-
tion of Zn led to the disappearance of the fast
radioligand dissociation rate, and the kinetics of [3H]-
8-OH-DPAT became monophasic. These results suggest
that Zn modifies receptor conformation, reducing ago-
nist radioligand dissociation, which is in line with the
enhancing effects exerted by Zn in the competition-like
experiments.
As detailed in Table 2, [3H]-8-OH-DPAT (2.5 nM)
binds at 5-HT1ARs with an association rate constant
(kon) of 3.4±0.4×10
8 M−1 min−1. In the presence of
10 μM of Zn ions, a small increase in the association
rate was observed, while at a higher concentration
(500 μM), Zn had no effect on the kon values.
Behavioural Studies
Effects of Zn Treatment on the LLR, FBP and FT in Rats
8-OH-DPAT (1 mg/kg), the 5-HT1A agonist, induced LLR
(p<0.001) in the rats. Zn, given at a dose of 2 and 5 mg/kg,
and WAY-100635, a 5-HT1A antagonist, given at the dose of
0.1 mg/kg, did not evoke LLR; however, they blocked the
LLR induced by 8-OH-DPAT (Zn: p<0.05 for the dose of
2 mg/kg and p<0.001 for the dose of 5 mg/kg; p<0.01 for
WAY-100635, vs. 8-OH-DPAT) (see Table 3). When given at
the doses of 2, 5, 7.5 and 11.5 mg/kg, Zn did not induce FBP
Fig. 1 Effect of increasing concentrations of Zn on the saturation binding
of [3H]-8-OH-DPAT in 5-HT1A receptor-expressing HEK293 cells. a
Representative set of radioligand saturation binding curves obtained in
the absence and presence of Zn. b Nonlinear regression analysis of the
saturation data according to equation 1
Table 1 Effects of Zn2+ on KD
and Bmax values of [
3H]8-OH-
DPAT obtained in saturation
binding experiments in 5-HT1A
receptors in HEK293 cells
Zn2+ [μM] 0 10 100 500 1000 2500 5000
KD [nM] 2.9±0.1 5.0±0.1 6.0±0.4 6.9±0.2 8.2±0.9 8.6±0.6 9.6±0.6
Bmax [pM/mg prot] 4.5±0.3 5.8±0.7* 6.2±2.0 4.7±0.7 4.0±0.6 3.1±1.2* 2.5±0.8*
*p<0.05
Fig. 2 The ‘bell-shaped’ Zn titration curve obtained in the competition-
like experiments, with the enhancement (~10 μM of Zn) and inhibition
(above 100 μM of Zn) of [3H]-8-OH-DPAT binding at 5-HT1ARs. The
curve was generated by fitting the data to equation 2 (a). Displacement of
specific [3H]-8-OH-DPAT binding by 5-HT in the absence (black circle;
Ki=8.7±0.6 nM) or presence of 10 μM (black square; Ki=5.4±0.2 nM;
p<0.05) and 500 μM (black triangle; Ki=8.1±0.6 nM) of Zn (b)
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or FT in the rats (see Table 4); however, at the higher doses of
11.5 mg/kg (p<0.001), 7.5 and 11.5 mg/kg (p<0.001 and
p<0.01, respectively), Zn blocked the 8-OH-DPAT-induced
FBP and FT.
Effects of Zn Treatment on the Body Temperature of Rats
and Mice
As shown in Fig. 4, 8-OH-DPAT (5 mg/kg) induced a signif-
icant decrease in body temperature of the mice (Fig. 4a) and in
rats (Fig. 4b) compared to saline group (p<0.001). Similarly
to 8-OH-DPAT, Zn significantly and dose-dependently de-
creased body temperature of the mice at both 30 (p<0.01)
and 60 min (p<0.01) after administration (Fig. 4a). Zn also
significantly decreased the body temperature of the rats, at
both 30 min (p<0.01 for the dose of 11.5 mg/kg, and
p<0.05 for the dose of 7.5 mg/kg) and 60 min after the injec-
tion (p<0.01 for the dose of 11.5 mg/kg; p<0.01 for the dose
of 7.5 mg/kg; and p<0.05 for the dose of 5 mg/kg) (Fig. 4b).
Effects of Zn Treatment on the Body Temperature
of the 5-HT1A Autoreceptor KO Mice
The effect of Zn treatment on the body temperature of the 5-
HT1A autoreceptor KOmice was shown in Fig. 4c. There was
no difference in basal body temperature between the wild-type
and 5-HT1A autoreceptor KO mice (37.7±0.23 and 37.9±
0.19, respectively). Zn administered at a dose of 5 mg /kg,
decreased the body temperature of the wild-type mice but
not of the autoreceptor KO mice (p<0.05 at 30 min and p=
0.06 at 60 min).
Effect of Zn in the FST
Rats As shown in Fig. 5a, Zn administered at a dose of
2 mg/kg but not 1 mg/kg significantly decreased the
Fig. 3 Effect of Zn on the dissociation (a) and association (b) rates of
[3H]-8-OH-DPAT in the absence (black circle) or presence of 10 μM
(black square) and 500 μM (black triangle) of Zn
Table 2 Association and dissociation rate constants of [3H]-8-OH-
DPAT obtained in the kinetic experiments in the absence and presence
of Zn
kon [M
−1 min−1] koff fast [min
−1] koff slow [min
−1]
Control 3.4±0.4×10+8 2.33±0.31 0.21±0.02
+10 μM Zn2+ 6.4±0.8×10+8* 0.25±0.04a
+500 μM Zn2+ 3.6±0.3×10+8 0.58±0.07** 0.06±0.02**
*p<0.07; **p<0.05
a one phase
Table 3 Lower lip retraction score as a function of 8-OH-DPAT for the
Zn, WAY-100635 and control groups
Mean±LLR score
Treatment (mg/kg) (A) VEH (B) 8-OH-DPAT 1 mg/kg
VEH 0.0±0.0 2.25±0.46###
Zn 2 0.0±0.0 1.17±0.98*
Zn 5 0.0±0.0 0.46±0.75***
WAY 100635 0.1 0.0±0.0 0.67±0.76**
(A) Each animal was scored for LLR three times, 15, 30 and 45 min after
the administration of Zn as follows: 0=lower incisors not visible, 0.5=
partly visible and 1=completely visible. The maximum total score was
3/rat. Zn was administered at doses of 2 and 5 mg Zn/kg. (B) The effect of
Zn and WAY-100635 on the LLR induced by 8-OH-DPAT was scored
using the same scale. Zn and WAY-100635 was administered 45 min
before 8-OH-DPAT and the animals were scored 15, 30 and 45 min after
8-OH-DPAT treatment. The values represent the mean±SEM (n=8–10
rats per group)
### p<0.01 vs. VEH; *p<0.05, **p<0.01 and ***p<0.001 vs. 8-OH-
DPAT. Statistical analysis was performed using one-wayANOVA follow-
ed by Dunnett’s post hoc test
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immobility time of the rats in the FST (p<0.01 and p>0.05,
respectively). 8-OH-DPATadministered at a dose of 0.3 mg/kg
(p<0.05) but not 0.1mg/kg (p>0.05) decreased the immobil-
ity time of the rats in the FST. Zn given jointly with 8-OH-
DPATat thedoses thatwere ineffective in theFSTsignificant-
ly decreased the immobility time of the rats (p<0.01) com-
pared to the VEH-treated group. As shown in Fig. 5b, Zn at a
dose of 2 and 5mg/kg significantly decreased the immobility
timeof the rats in theFST (p<0.05andp<0.01, respectively).
Whengivenalone,WAY-100635, anantagonist of5-HT1ARs
(0.1 mg/kg), did not change the behaviour of the animals in
this test, but it antagonized the Zn-induced decrease in the
immobility time of the rats (p<0.05 vs. the Zn-treated groups).
5-HT1A Autoreceptor KOMice Zn administered at a dose of
5 mg/kg induced a slight (30 %) decrease in the immobility
time of the 5-HT1A autoreceptor KO mice compared to the
VEH-treated KO mice (see Fig. 6b), while in wild-type mice
(see Fig. 6a), a significant decrease in immobility time after Zn
treatment was observed (p<0.05).
Discussion
Receptor Binding Studies
As an endogenous trace element, Zn has been suggested to act
as an allosteric modulator of a number of G protein-coupled
receptors, such as dopamine D1, D2 and D4; melanocortin
MC1 and MC4; α1A and β2 adrenergic; μ, κ and δ opioid;
and serotonin 5-HT1A receptors [28]. Despite the previous
identification of Zn ions as allosteric inhibitors of both ago-
nists and antagonists of 5-HT1ARs [13], the exact mechanism
of Zn’s action in relation to orthosteric agonists appears
complex and is not fully understood. Thus, in the present
study, an extended set of in vitro radioligand binding experi-
ments (saturation, competition-like and kinetic tests) were un-
dertaken using [3H]-8-OH-DPAT as an agonist probe to fur-
ther characterize the effects of Zn on 5-HT1ARs.
Consistent with the data presented by Barrondo and Salles
for native tissue [13], the results of the current saturation ex-
periments using stable expression of 5-HT1ARs in HEK293
cells suggest negative allosteric modulation of Zn on [3H]-8-
OH-DPAT binding (α=0.37). Nevertheless, a model of nega-
tively cooperative interactions does not account for all of the
additional data obtained in the study.
At first, Zn tested alone in a competition-like assay with
[3H]-8-OH-DPAT yielded a bell-shaped binding curve, with a
marked increase in agonist radioligand binding at low modu-
lator concentrations and a decrease in binding at high concen-
trations (Fig. 2a). This type of curve was also shown for sev-
eral adenosine A1 allosteric modulators investigated in agonist
radioligand binding assays [27, 29, 30]. The results of those
studies have invariably been interpreted as evidence that the
investigated molecules recognize the allosteric site at low con-
centrations but also bind to the orthosteric site at higher con-
centrations, combining the two mechanisms of action: alloste-
ric enhancement and competitive inhibition [27, 29, 30].
Interestingly, in the competition experiments, an enhance-
ment of agonist binding to 5-HT1ARs was evident in the pres-
ence of 10 μM of Zn for 5-HT only, while a concentration of
500 μM of Zn did not change the Ki values for this orthosteric
agonist. Likewise, the association kinetics of [3H]-8-OH-
DPAT showed small increase in association rate (kon) at a
low (10 μM) concentration of Zn ions (Table 2), and the lack
of statistically significant effects on kon values at a higher Zn
concentration (500 μM) was observed (Table 2, Fig. 3). How-
ever, the results of the dissociation kinetic experiments
Table 4 Induction of behavioural
syndrome by Zn (A) and the
effect of Zn on the 8-OH-DPAT-
induced behavioural syndrome
(B)
Treatment Dose (mg/kg) Mean±SEM behavioural score
(A) VEH (B) 8-OH-DPAT
FBP FT FBP FT
VEH 0.0±0.0 0.0±0.0 7.83±0.7 7.5±0.6
Zn 2 0.2±0.2 0.3±0.2 7.7±0.3 7.1±0.6
5 0.3±0.3 0.2±0.2 7.5±0.8 7.5±0.5
7.5 0.5±0.5 0.2±0.2 7.0±0.3 5.0±0.6**
11.5 0.5±0.2 0.2±0.2 3.4±0.6*** 0.4±0.2***
(A) In each animal, the Zn-induced behavioural syndromewas scored at 3, 6, 9, 12 and 15min after Zn treatment.
FBP, flat body posture, and FT, forepaw treading, were scored using the following scale: 0=absent, 1=equivocal,
and 2=present. The maximum score, which was summed over 5 observation periods, was 10 for each symptom/
rat. (B) The effect of Zn on the behavioural syndrome induced by 8-OH-DPATwas scored using the same scale.
Zn was administered 60 min before 8-OH-DPAT (5mg/kg), and the animals were scored at 3, 6, 9, 12 and 15min
after 8-OH-DPAT treatment. The data represent the mean±SEM for n=6 rats
***p<0.001; **p<0.01, compared to the VEH+8-OH-DPAT group. Statistical analysis was performed using
one-way ANOVA followed by Dunnett’s post hoc test
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showed that both concentrations of Zn used slowed the
radioligand dissociation rates, which is a characteristic of pos-
itive allosteric modulation (Table 2, Fig. 3).
The complex pattern of presently obtained data, when the
behaviour of Zn in the saturation experiments and competition
and kinetic assays are compared, supports the conclusion that
the previously assumed negatively cooperative model is not a
complete description of Zn’s effects on agonist binding. Be-
cause Zn displayed negative cooperative interactions with
[3H]-8-OH-DPAT in the saturation experiments but caused
an increase in Bmax values at low concentrations and directly
showed properties of positive allosteric modulation in both the
competition-like and kinetic experiments, a dual mode of Zn
action against agonist binding at 5-HT1ARs should be
considered.
It is worth noting that in the case mentioned above, in
which adenosine A1 ligands showed positive cooperativity in
interactions with agonists, when the same modulators were
tested against antagonist probes, they were characterized only
by inhibitory properties [29, 30]. Similar probe dependence
can be observed by comparing the data we obtained for the
effects of Zn on agonist binding at 5-HT1ARs with earlier
results describing clear negative modulation of antagonist
([3H]-WAY-100635) binding [13].
It should be mentioned that a complex mechanism of Zn
action has also been detected for several other proteins. In
electrophysiological studies of 5-HT3 receptor, low concentra-
tions of Zn (0.3–10 μM) enhanced and high concentrations of
Zn (30–200 μM) depressed, the 5-HT-induced response [31].
Biphasic effects involving potentiation at sub-micromolar and
Fig. 4 Effect of Zn and 8-OH-
DPAT on body temperature in
mice (a), rats (b) and 5-HT1A
+/+
(WT) and 5-HT1A autoreceptor
−/−
(KO) mice (c). The change in
body temperature was calculated
for each animal by comparing the
baseline temperature to the
temperature reached 30 and
60 min following Zn or 8-OH-
DPAT administration. WAY-
100635 at a dose of 0.1 mg/kg
was administered (sc) 15 min
before the Zn (a). The test was
performed 30 and 60 min after
injection of Zn (5 mg/kg) (ip).
The data bars represent the mean
±SEM for n=8 (mice); n=5
(WT mice) and n=8 (KO mice)
and n=6 (rats) animals. *p<0.05;
**p<0.01; ***p<0.001,
compared to the VEH group.
Statistical analysis was performed
using one-way ANOVA followed
by Dunnett’s post hoc test (a and
b) and Student’s t test (c)
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inhibition at sub-millimolar Zn concentrations have been de-
tected for glycine receptors [32]. Similar effects were also
demonstrated for β2 adrenergic receptors, in which the pres-
ence of 5 μM of Zn enhanced agonist affinity, whereas
500 μM of Zn inhibited antagonist binding [33].
Summing up, Zn released into synaptic space from neuro-
nal vesicles (of mostly glutamatergic terminals) was found to
act at various channels and membrane receptors and these
modulatory effects of Zn can be positive or negative depend-
ing on its concentration. The exact amount of Zn release is
controversial; however, many laboratories have indicated that
Zn increases in the extracellular space may reach 1–100 μM
[34–36]. Therefore, it seems that the effects observed at lower
Zn concentrations should be physiologically more relevant,
especially that the elevation of extracellular Zn level, over
300 μM, is reported as neurotoxic [37].
In Vivo Studies
The results of in vivo studies provide evidence that Zn is likely
to have both an agonist and antagonist profile at 5-HT1A re-
ceptors that could be a consequence of dual Zn effects at 5-
HT1A receptors suggested by in vitro studies.
Body Temperature
Induction of hypothermia in response to the administration of
8-OH-DPAT is one of the parameters which have been pro-
posed as an index of 5-HT1AR autoreceptor mediated activity
[23, 38]. In our study, Zn decreased the body temperature in
mice and the intensity of this effect was similar to that ob-
served for 8-OH-DPAT. Furthermore, pretreatment with
WAY-100635, the 5-HT1AR antagonist, abolished the effect
induced by Zn. On the other hand, our studies using 5-HT1A
autoreceptor KO mice showed that lack of this receptor
completely blocked the hypothermia induced by Zn, while
in wild-type littermate mice, a consistent decrease in body
temperature was observed. These results are consistent with
those showing that hypothermic effect of 5-HT1AR agonists in
mice is mediated by presynaptic 5-HT1AR [38, 39] and
Fig. 5 Effect of Zn and 8-OH-DPAT given alone and jointly using the
doses that did not affect immobility time in the FST in rats (a) and the
effect of pretreatment with WAY-100635 on Zn-induced reduction in
immobility time (b). Zn and 8-OH-DPAT were administered alone or
jointly 30 min before the FST (a). WAY-100635 was administered
15 min before the Zn treatment, and the FST test was performed
30 min after Zn treatment (b). The values represent the mean±SEM
(n=5–8 rats). *p<0.05; **p<0.01 vs. the VEH group; #p<0.05 vs. the
Zn treatment group. Statistical analysis was performed using one-way
ANOVA followed by Dunnett’s post hoc test
Fig. 6 The effect of Zn treatment
on the immobility time in the FST
in the 5-HT1A
+/+ (WT) (a) and 5-
HT1A autoreceptor
−/− (KO) (b)
mice. Zn at the dose of 5 mg/kg
was administered 30 min before
the FST. The data bars represent
the mean±SEM for n=3–5 mice.
*p<0.05 compared to the VEH
group. Statistical analysis was
performed using Student’s t test
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indicate an agonist-like profile of Zn at presynaptic 5-
HT1ARs, perhaps enhancing the action of endogenous 5-HT.
In the present studies, we found that Zn can also induce
hypothermia in rats; however, this effect was observed at
higher doses than in mice. It is still controversial which 5-
HT1ARs namely pre- or postsynaptic are responsible for the
induction of decrease in the body temperature in rats. Some
data [23, 40, 41] suggest that postsynaptic rather than presyn-
aptic 5-HT1AR is implicated in this effect in rats. Despite that
these data further suggest the agonist-like profile of Zn at 5-
HT1AR as in mice.
Lower Lip Retraction and 5-HT Syndrome
Another behavioural approach used to characterize 5-
HT1AR mediated activity is the induction of lower lip
retraction (LLR). As shown by Berendsen et al. [20,
21], LLR was induced by the 8-OH-DPAT, buspirone,
ipsapirone—agonists or partial agonists with a high af-
finity for 5-HT1A binding sites in rat brain but not by
serotonergic agents such as 5-MeO-DMT, mCPP or DOI
with weaker affinity for 5-HT1AR but with high affinity
for 5-HT2AR, 5-HT2B/2CR or 5-HT2A/2CR, respectively
[20, 21]. The effect induced by 8-OH-DPAT was atten-
uated by 5-HT1A antagonists such as WAY-100135 or
WAY-100635 (which by themselves did not produce
the LLR [42]), as well as by the above-mentioned non-
selective serotonergic agents of moderate 5-HT1AR af-
finity which can act as antagonists of 5-HT1AR. In the
case of location of receptors mediating this effect, it is
suggested that LLR produced by the selective 5-HT1AR
agonists has been attributed to autoreceptor activation
[20, 21].
In our study, Zn did not induce LLR but significantly and
dose-dependently blocked the LLR induced by 8-OH-DPAT.
As was mentioned above, the LLR is specific only for com-
pounds with high efficacy at 5-HT1ARs; thus, the lack of this
effect after Zn treatment with simultaneous blockade of 8-OH-
DPAT action might result from the fact that Zn, like 5-MeO-
DMT, mCPP or DOI, can also modulate other types of sero-
tonin receptors, especially from 5-HT2R family. It was, for
instance, found that chronic Zn administration increased the
density of 5-HT2A serotonin receptors in the frontal cortex [9].
Moreover, ritanserin, the 5-HT2A/C receptor antagonist,
blocked the antidepressant-like effect of Zn in the FST [10].
Another behavioural effect induced by 5-HT1AR agonists
is serotonin syndrome that is believed to reflect postsynaptic
5-HT1AR activation. It is observed after higher doses of 8-OH-
DPAT and is associated with the enhanced 5-HT synthesis
[43]. In the behavioural syndrome tests, Zn given alone did
not evoke flat body posture or forepaw trading, however, in
the higher doses strongly inhibited both FBP and FT showing
a postsynaptic 5-HT1AR antagonist-like profile.
Taken together, our data suggest that Zn has concentration-
dependent actions in the above-mentioned behavioural re-
sponses that are mediated by 5-HT1ARs. Thus, LLR and hy-
pothermia are produced following administration of low doses
of Zn or 8-OH-DPAT and are attributed selectively to
autoreceptor activation. Interestingly, Zn induced hypother-
mia in mice at lower doses than in rats. Higher doses of Zn
were needed to reverse 8-OH-DPAT induced LLR, and only
higher doses of Zn blocked 8-OH-DPAT induced FBP/FT.
These results are consistent with a potentiating effect of Zn
on agonist actions at 5-HT1AR at low doses and an antagonist
effect at higher doses, although the absolute dose depends on
the animal model and behaviour studied.
Forced Swim Test
The 5-HT1AR agonist 8-OH-DPAT and several others se-
rotonin agonists with varying degrees of selectivity for
different subtypes of 5-HTRs produce antidepressant-like
behaviour in the FST. Wieland and Lucki, [44] showed
that p-chlorophenylalanine (pCPA), which is known to
reduce the concentration of serotonin in the brain by
inhibiting its biosynthesis, did not block the antidepres-
sant effect of 8-OH-DPAT in the FST in rats. These and
other studies suggest that the antidepressant-like effects of
5-HT1AR agonists are mediated by postsynaptic 5-
HT1ARs [19, 44].
Zn also induces antidepressant-like effects in the FST both
in rats and mice [10, 45–48]. Our earlier studies performed in
mice [10] and the present studies in rats indicated that pretreat-
ment with WAY-100635 blocked the effect of Zn. Further-
more, when Zn was given together with 8-OH-DPAT at the
doses that were ineffective in the FST, it decreased immobility
time, which suggests the additive effect of both compounds in
this test and the agonist-like effect of Zn in the FST. Interest-
ingly, the results of the 5-HT1A autoreceptor KO mice in the
FST demonstrated that the lack of presynaptic 5-HT1ARs only
partially blocked the anti-immobility effect induced by Zn in
mice; however, pCPA pretreatment completely blocked the
antidepressant-like effect of Zn in mice [10]. These data sug-
gests that presynaptic receptors may be also implicated in the
Zn-induced effects in the FST. These results also showed that
Zn does not work without endogenous serotonin, which can
be attributed to its allosteric mechanism of 5-HT1AR regula-
tion because allosteric modulators may act only in conjunction
with physiological receptor activation. It should be noted,
however, that the allosteric nature of Zn described previously
[13], which suggests only the inhibition of both agonist and
antagonist interactions at 5-HT1ARs, cannot explain the
agonistic-like effects of Zn observed in our in vivo studies.
In contrast, the current in vitro binding data, which showed
characteristics of positive allosteric modulation in the pres-
ence of 10 μM of Zn and the inhibition of agonist action at
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sub-millimolar Zn concentrations, are more coherent with the
results observed in vivo.
Conclusions
In summary, our studies provide new data regarding the dual
mechanism of Zn action at 5-HT1ARs, which may underlie its
antidepressant-like effects observed in the behavioural tests.
The in vitro radioligand results revealed biphasic effects, in-
volving allosteric potentiation of agonist binding at sub-
micromolar Zn concentrations and inhibition at sub-
millimolar Zn concentrations. Given the therapeutic potential
of Zn, the in vitro results obtained for lower Zn concentration
(10 μM) are within the range of reported extracellular free Zn
concentrations (1–100 μM) and thus potentiating effects may
be physiologically more relevant than inhibition observed
using higher Zn concentrations at which toxic effects may be
expected.
In behavioural paradigms, which are commonly used to
distinguish the pharmacological profile of new com-
pounds at 5-HT1AR, both agonist and antagonist-like ef-
fects of Zn at 5-HT1ARs were found, and these data are
consistent with results from the in vitro radioligand stud-
ies revealing biphasic Zn effects at 5-HT1AR, involving
allosteric potentiation of agonist binding and inhibition.
Taking into account results of in vivo studies with the
use of wild-type and 5-HT1A autoreceptor knockout ani-
mals, it seems that Zn can affect both pre- and postsyn-
aptic 5-HT1ARs. It should be, however, stressed that more
studies are needed to explain this complex mechanism of
antidepressant-like effect of Zn via modulation of seroto-
nin system, especially that there are many controversies in
the literature concerning the participation of the pre- and
postsynaptic 5-HT1ARs in the behavioural tests in rodents.
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